Shares of Harvard Bioscience Inc. (NASDAQ:HBIO) rose 1.6% on Friday . The stock traded as high as $2.64 and last traded at $2.60, with a volume of 66,234 shares. The stock had previously closed at $2.56.

Separately, Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th.

The firm has a 50 day moving average of $2.84 and a 200-day moving average of $2.99. The stock’s market cap is $89.90 million.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.03 EPS for the quarter, meeting analysts’ consensus estimates of $0.03. The firm had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $26.60 million. On average, equities analysts anticipate that Harvard Bioscience Inc. will post $0.16 EPS for the current year.

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.